← Leaderboards
Colm M Morrissey
Fred Hutchinson Cancer Research Center
$3,479,548
Attributed
$3,479,548
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $604.3K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,479,548 · 3
By mechanism
P50$3,479,548 · 3
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Joshi James Alumkal$6,560,072
- Julian A Simon$13,150,957
- Taran Singh Gujral$3,227,225
- Gavin Ha$4,673,787
- Mads Daugaard$838,161
Others in their field
Other Emerging Leaders on “Biopsy”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Russell T Hepple · California Pacific Med Ctr Res Institute$12,760,565
- Gabriel Nestor Sanchez · Enspectra Health, Inc.$7,941,485
- Todd Levine · Cnd Life Sciences, Inc.$7,820,585
Research focus
BiopsyMaintenanceMalignant Neoplasm Of ProstateHistologicAutopsyClinical TrialsPacific NorthwestDesignXenograft ProcedureBiological ModelsTumorIn Situ HybridizationCollectionClinical ResearchClinical DataInstitutional Review BoardsHistologyEnsureLaboratoriesConfidentiality Of Patient InformationClinicFoundationsDatabasesCancer Research Project
Grant awards (15)
Core B: Biospecimen and Pathology$237,841
P50 · FY2025 · CA · contact PI
Core B: Biospecimen and Pathology$289,593
P50 · FY2024 · CA · contact PI
Core B: Biospecimen and Pathology$316,067
P50 · FY2023 · CA · contact PI
Core B: Biospecimen and Pathology Core$256,292
P50 · FY2022 · CA · contact PI
Project 2: Targeting Emergent Vulnerabilities in AR-Inactive Prostate Cancer$216,126
P50 · FY2022 · CA · contact PI
Core B: Biospecimen and Pathology Core$136,526
P50 · FY2021 · CA · contact PI
Core B: Biospecimen and Pathology Core$129,899
P50 · FY2021 · CA · contact PI
Project 2: Targeting Emergent Vulnerabilities in AR-Inactive Prostate Cancer$116,667
P50 · FY2021 · CA · contact PI
Project 2: Targeting Emergent Vulnerabilities in AR-Inactive Prostate Cancer$110,615
P50 · FY2021 · CA · contact PI
Core B: Biospecimen and Pathology Core$323,707
P50 · FY2020 · CA · contact PI
Project 2: Targeting Emergent Vulnerabilities in AR-Inactive Prostate Cancer$280,575
P50 · FY2020 · CA · contact PI
Core B: Biospecimen and Pathology Core$270,185
P50 · FY2019 · CA · contact PI
Project 2: Targeting Emergent Vulnerabilities in AR-Inactive Prostate Cancer$230,091
P50 · FY2019 · CA · contact PI
Core B: Biospecimen and Pathology Core$290,521
P50 · FY2018 · CA · contact PI
Project 2: Targeting Emergent Vulnerabilities in AR-Inactive Prostate Cancer$274,843
P50 · FY2018 · CA · contact PI